News
SPRO
2.260
+11.88%
0.240
Spero Therapeutics Expands Stock Incentive Plan and Authorization
TipRanks · 1d ago
Spero Therapeutics shareholders approved increase in authorized common shares to 240 million
PUBT · 1d ago
Spero Therapeutics secures FDA approval for Utebzi
TipRanks · 4d ago
Spero Therapeutics says FDA approves Utebzi oral antibiotic for complicated UTIs in adults
PUBT · 4d ago
Weekly Report: what happened at SPRO last week (0615-0619)?
Weekly Report · 4d ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 06/19 09:09
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
Seeking Alpha · 06/18 19:41
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 06/18 12:06
At a glance: stocks gapping up premarket
Seeking Alpha · 06/18 11:29
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Benzinga · 06/18 10:10
Biggest stock movers Thursday: INTC, RUM, SPRO and more
Seeking Alpha · 06/18 10:02
Spero: FDA Approves Utebzi, The First Oral Carbapenem For Complicated UTIs In Adults; Stock Up
NASDAQ · 06/18 03:53
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 06/17 21:06
GSK/Spero Therapeutics announces FDA Utebzi approval in U.S.
TipRanks · 06/17 20:25
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
Benzinga · 06/17 17:29
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 06/17 17:06
Spero Therapeutics says FDA approves Utebzi oral antibiotic for adults with complicated UTIs
PUBT · 06/17 16:40
GSK, Spero win approval of Utebzi for complicated urinary tract infections
Seeking Alpha · 06/17 15:30
GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract Infections
Benzinga · 06/17 15:24
GSK, Spero Therapeutics announce FDA approval of Utebzi
TipRanks · 06/17 15:17
More
Webull provides a variety of real-time SPRO stock news. You can receive the latest news about Spero Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.